Sixty-four to 90% of breast cancers that occur in BRCA1 mutation carriers (BRCA1 carriers) are estrogen receptor-negative (ER-), progesterone receptor-negative (PR-) and lack HER2 protein overexpression and gene amplification, so called "triple negative" breast cancers [1-8]. This evidence concerns the gene PGR and breast cancer.